Blood Pressure Management in Hemodialysis Patients

Introduction to Blood Pressure Management

• The American Journal of Kidney Diseases recommends that blood pressure should be managed in hemodialysis patients with attention to both fluid status management and appropriate antihypertensive medication selection, with predialysis and postdialysis blood pressure goals of <140/90 mmHg and <130/80 mmHg, respectively 1, 2

Assessment and Measurement Considerations

• Blood pressure should be measured with the patient seated quietly for at least 5 minutes, feet on floor, arm supported at heart level, as recommended by the American Journal of Kidney Diseases 3
• In patients who have undergone multiple vascular access procedures in both arms, blood pressure should be measured in the thighs or legs using appropriate cuff size and in the supine position, according to the American Journal of Kidney Diseases and the Praxis Medical Insights 1, 2
• Home blood pressure monitoring or ambulatory blood pressure monitoring provides more accurate assessment of true blood pressure than in-center measurements, as stated by the Circulation journal and the Praxis Medical Insights 4, 2, 3

Volume Management

• The American Journal of Kidney Diseases suggests focusing first on achieving dry weight through appropriate ultrafiltration during dialysis sessions, and implementing strict dietary sodium restriction (2-3 g/day) with regular counseling by dietitians 1, 3
• Consider the following strategies for difficult-to-control hypertension, as recommended by the American Journal of Kidney Diseases and the Kidney International journal: increased ultrafiltration, longer dialysis sessions, more frequent dialysis (>3 treatments per week), and intradialytic sodium modeling to minimize hypotension 1, 5

Pharmacological Management

• If volume control is insufficient, the American Journal of Kidney Diseases recommends initiating antihypertensive medications, with ACE inhibitors or ARBs as first-line agents because they cause greater regression of left ventricular hypertrophy, reduce sympathetic nerve activity, and may improve endothelial function and reduce oxidative stress 1, 6, 3
• Beta-blockers are preferred in patients with coronary artery disease or heart failure, according to the Kidney International journal and the Praxis Medical Insights 6, 2
• Calcium channel blockers have demonstrated efficacy in reducing cardiovascular events in hemodialysis patients with hypertension, as stated by the Kidney International journal 6, 5

Medication Administration Considerations

• Antihypertensive drugs should be given preferentially at night to reduce nocturnal blood pressure surge and minimize intradialytic hypotension, as recommended by the American Journal of Kidney Diseases 1
• Consider the dialyzability of medications when selecting agents, according to the American Journal of Kidney Diseases and the Praxis Medical Insights 1, 3

Monitoring and Special Considerations

• Monitor for orthostatic hypotension, particularly in elderly patients, as recommended by the Praxis Medical Insights 2
• Be cautious with excessive blood pressure reduction as a U-shaped relationship exists between blood pressure and mortality in dialysis patients, as stated by the Circulation journal and the Praxis Medical Insights 4, 3
• Evaluate for secondary causes of resistant hypertension if blood pressure remains uncontrolled despite optimal therapy, according to the Praxis Medical Insights 3

Common Pitfalls to Avoid

• Relying solely on predialysis or postdialysis blood pressure measurements, which correlate poorly with interdialytic ambulatory blood pressure, as stated by the Circulation journal 7, 4
• Neglecting volume status assessment before initiating or increasing antihypertensive medications, according to the American Journal of Kidney Diseases and the Praxis Medical Insights 1, 3

Management of Hypertension in Hemodialysis Patients

Volume Management

• Consider lower dialysate sodium concentrations (around 135 mmol/L rather than 140 mmol/L) to achieve proper volume control and reduce hypertension, as recommended by the American Journal of Kidney Diseases 8, 9, 10
• Avoid high dialysate sodium concentration and sodium profiling as these can aggravate thirst, fluid gain, and hypertension, according to the American Journal of Kidney Diseases 8, 9, 10

Special Considerations

• Preserve residual kidney function when possible, as it is an important predictor of patient survival, as stated by the American Journal of Kidney Diseases 9, 10

Loop Diuretics

• Large doses of potent loop diuretics (such as furosemide) can be administered to promote sodium and water loss in patients with residual kidney function, as recommended by the American Journal of Kidney Diseases 8, 9, 10
• However, diuretic use should be approached with caution, according to the American Journal of Kidney Diseases 8, 9, 10

Expected Blood Pressure Reduction with Metoprolol in ESRD Patients

Metoprolol in ESRD Patients

• Beta-blockers like metoprolol are considered appropriate antihypertensive agents for patients on dialysis, but dosing considerations are important 11
• Metoprolol is highly dialyzable, which may affect its efficacy in patients on hemodialysis 11

Blood Pressure Management in Dialysis Patients

• Volume management should be the primary approach to blood pressure control in dialysis patients before relying on antihypertensive medications 11
• When antihypertensive medications are needed, they should be selected based on patient characteristics, cardiovascular indications, and dialyzability 11

Considerations for Metoprolol Dosing in ESRD

• The dialyzability of metoprolol means it may have reduced efficacy during the dialysis period 11
• Some retrospective studies suggest that highly dialyzable beta-blockers like metoprolol may be associated with higher mortality compared to non-dialyzable beta-blockers, possibly due to reduced intradialytic protection against arrhythmias 11
• However, other studies indicate that metoprolol may have better outcomes than non-dialyzable beta-blockers like carvedilol due to lower risk of intradialytic hypotension 11

Expected Blood Pressure Response

• Blood pressure response to metoprolol in ESRD patients may be affected by volume status of the patient 11
• Blood pressure response to metoprolol in ESRD patients may be affected by timing of medication administration relative to dialysis sessions 11

Common Pitfalls to Avoid

• Failing to consider the dialyzability of medications when selecting agents and dosing schedules 11

Target MAP During Hemodialysis

Primary Approach: Volume Management First

• The American Journal of Kidney Diseases recommends volume control through ultrafiltration to achieve true dry weight as the first-line strategy for blood pressure management during hemodialysis, not pharmacological intervention 12
• Extracellular volume expansion is the primary driver of hypertension in hemodialysis patients, making dry weight achievement essential before considering medication adjustments 12
• Gradual dry weight reduction (0.1 kg per 10 kg body weight) over 4-12 weeks reduces ambulatory blood pressure by approximately 7 mmHg while minimizing adverse events 12

Specific MAP Targets and Rationale

• The Critical Care Medicine society recommends maintaining MAP ≥65 mmHg during hemodialysis sessions to ensure adequate tissue perfusion while avoiding the increased mortality associated with excessive hypotension 13
• Below MAP of 65 mmHg, tissue perfusion becomes linearly dependent on arterial pressure as autoregulation fails 13
• Targeting MAP of 65 mmHg versus 85 mmHg shows no mortality difference but reduces arrhythmia risk and vasopressor requirements 13
• Post-dialytic drops in systolic blood pressure up to 30 mmHg are associated with improved survival, but greater decreases correlate with higher mortality 14

Special Populations

• In elderly patients (>75 years), targeting MAP of 60-65 mmHg may reduce mortality compared to higher targets of 75-80 mmHg 13
• Patients with chronic hypertension may benefit from slightly higher MAP targets (up to 85 mmHg) to reduce need for renal replacement therapy 13

Hypertension Management in Hemodialysis Patients

Primary Strategy: Volume Control First

• The American Journal of Kidney Diseases recommends implementing strict dietary sodium restriction to 2-3 g/day with regular dietitian counseling to optimize volume and blood pressure control 15
• The American Journal of Kidney Diseases suggests considering extended dialysis time or increased frequency, as the Tassin experience demonstrated that 89% of hypertensive patients no longer required antihypertensive medications after 3 months of long, slow dialysis combined with sodium restriction 15

Blood Pressure Targets

• The American Journal of Kidney Diseases recommends targeting predialysis blood pressure ≤140/90 mmHg and postdialysis blood pressure <130/80 mmHg to minimize left ventricular hypertrophy and mortality in dialysis patients 16

Pharmacological Management

• The American Journal of Kidney Diseases recommends initiating ACE inhibitors or ARBs as first-line antihypertensive agents if volume control is insufficient after 4-12 weeks of optimized ultrafiltration and sodium restriction 16
• The American Journal of Kidney Diseases suggests that ACE inhibitors or ARBs are preferred because they cause greater regression of left ventricular hypertrophy, reduce sympathetic nerve activity, improve endothelial function, and are associated with decreased mortality in dialysis patients 16
• The American Journal of Kidney Diseases recommends using beta-blockers in patients with coronary artery disease, prior myocardial infarction, or heart failure, as they are associated with decreased mortality in chronic kidney disease 16
• The American Journal of Kidney Diseases suggests adding calcium channel blockers or alpha-adrenergic blockers as third-line agents if blood pressure remains uncontrolled, as they have demonstrated efficacy in reducing cardiovascular events 16

Special Populations and Considerations

• The American Journal of Kidney Diseases recognizes that erythropoietin therapy can worsen hypertension, particularly in patients with pre-existing hypertension, severe anemia, or rapid anemia correction 16

Blood Pressure Management During Dialysis

Introduction to Guideline Recommendations

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines emphasize that blood pressure management during dialysis depends on balancing multiple volume-related factors, with ultrafiltration rate being the critical dialysis parameter affecting hemodynamic stability 17, 18

Evidence-Based Interventions

• The KDIGO guidelines highlight the importance of volume status and achieving true dry weight as the primary determinant of blood pressure control in dialysis patients, although the specific citation for this fact is not provided, the overall emphasis on volume management is supported by 17, 18, 19
• Do not rely solely on pre- or post-dialysis blood pressure measurements for diagnosing hypertension; use home BP monitoring or ambulatory BP monitoring for superior risk prediction, as recommended by KDIGO 17, 18, 19

Gaps in Current Evidence

• There is a recognized lack of quality evidence regarding specific dialysis prescription parameters and their effects on blood pressure, including the impact of blood flow rate, as acknowledged by KDIGO 17, 20